Company: NCEL
Filing Date: 2025-01-31
Form Type: 6-K
Source: 0001213900-25-008826
Chunk: 2

Company: NewcelX Ltd.
Filing Date: 2025-01-31
Form: 6-K
Chunk 2
---
, the Company filed a registration statement on Form F-4 on December 30, 2023, including a proxy
statement/prospectus, with the SEC (the “F-4 Registration Statement”). The Company may also file other relevant documents
regarding the proposed transaction with the SEC, including an amendment to the F-4 Registration Statement. This document is not a substitute
for the proxy statement/prospectus or any other document that the Company may file with the SEC. The proxy statement (if and when available)
will be mailed to shareholders of the Company. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY
OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN
THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.
Investors and security holders will be able to obtain free copies of the proxy statement/prospectus (if and when available) and other
documents containing important information about the Company and the proposed transaction, once such documents are filed with the SEC
through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by the Company will be available
free of charge on the Company’s website at www.nlspharma.com.

Participants in the Solicitation

The
Company and certain of its respective directors and executive officers may be deemed to be participants in the solicitation of proxies
from the Company’s shareholders in respect of the proposed transaction. Information about the directors and executive officers of
the Company, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in the Company’s
Annual Report on Form 20-F for the fiscal year ended December 31, 2023, which was filed with the SEC on May 15, 2024. Other information
regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or
otherwise, are contained in the F-4 Registration Statement and other relevant materials to be filed with the SEC regarding the proposed
transaction when such materials become available. Investors should read the proxy statement/prospectus carefully when it becomes available
before making any voting or investment decisions. You may obtain free copies of these documents from the Company using the